Syngene International is currently trading at Rs. 565.40, up by 5.00 points or 0.89% from its previous closing of Rs. 560.40 on the BSE.
The scrip opened at Rs. 564.00 and has touched a high and low of Rs. 571.00 and Rs. 560.00 respectively. So far 1394 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 670.00 on 24-Jan-2018 and a 52 week low of Rs. 430.00 on 11-Aug-2017.
Last one week high and low of the scrip stood at Rs. 572.50 and Rs. 534.30 respectively. The current market cap of the company is Rs. 11308.00 crore.
The promoters holding in the company stood at 74.46%, while Institutions and Non-Institutions held 17.82% and 7.71% respectively.
Syngene International has signed Research and Development (R&D) agreement with GSK, a science-led global healthcare company. The multiyear agreement will focus on accelerating the discovery of new drug candidates using Syngene’s discovery services platforms.
As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs.
Syngene International is India’s largest Contract Research Services Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: